De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Shanghai Pioneer Holding Toekomstige groei
Future criteriumcontroles 0/6
Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Shanghai Pioneer Holding te voorspellen.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
Healthcare winstgroei | 19.6% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | None |
Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
Shareholders Should Be Pleased With Shanghai Pioneer Holding Ltd's (HKG:1345) Price
Jul 15Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024
Apr 24Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024
Apr 03Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 01Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks
Mar 22Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital
Feb 26Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?
Oct 21Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024
Sep 18Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024
Sep 01Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching
Aug 09Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 14Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 31Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly
Dec 15China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018
Sep 21China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Sep 02China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward
Jun 22China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064
Apr 14China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around
Jan 16These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely
Oct 11China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year
Sep 15China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056
Sep 01China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns
Aug 26Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture
May 22We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt
Apr 25Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?
Mar 14How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?
Feb 21Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?
Feb 03Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?
Jan 16China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet
Dec 29Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?
Dec 14China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment
Nov 29In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Shanghai Pioneer Holding onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
6/30/2024 | 1,648 | 164 | 55 | 124 | N/A |
3/31/2024 | 1,607 | 155 | -54 | 2 | N/A |
12/31/2023 | 1,567 | 146 | -163 | -119 | N/A |
9/30/2023 | 1,600 | 168 | -180 | -128 | N/A |
6/30/2023 | 1,634 | 190 | -198 | -137 | N/A |
3/31/2023 | 1,595 | 213 | -89 | -22 | N/A |
12/31/2022 | 1,556 | 235 | 19 | 93 | N/A |
9/30/2022 | 1,482 | 216 | 134 | 194 | N/A |
6/30/2022 | 1,408 | 196 | 250 | 296 | N/A |
3/31/2022 | 1,422 | 169 | 236 | 269 | N/A |
12/31/2021 | 1,435 | 143 | 222 | 242 | N/A |
9/30/2021 | 1,415 | 117 | 194 | 244 | N/A |
6/30/2021 | 1,395 | 91 | 166 | 246 | N/A |
3/31/2021 | 1,364 | 72 | 81 | 160 | N/A |
12/31/2020 | 1,332 | 52 | -4 | 74 | N/A |
9/30/2020 | 1,325 | 45 | -9 | 38 | N/A |
6/30/2020 | 1,318 | 37 | -15 | 2 | N/A |
3/31/2020 | 1,317 | 71 | 128 | 141 | N/A |
12/31/2019 | 1,316 | 105 | 272 | 281 | N/A |
9/30/2019 | 1,304 | 84 | 240 | 246 | N/A |
6/30/2019 | 1,293 | 63 | 208 | 212 | N/A |
3/31/2019 | 1,459 | 74 | 168 | 170 | N/A |
12/31/2018 | 1,624 | 85 | 128 | 129 | N/A |
9/30/2018 | 1,851 | 171 | 135 | 141 | N/A |
6/30/2018 | 2,077 | 258 | 142 | 153 | N/A |
3/31/2018 | 2,116 | 269 | N/A | 193 | N/A |
12/31/2017 | 2,154 | 279 | N/A | 234 | N/A |
9/30/2017 | 2,083 | 279 | N/A | 297 | N/A |
6/30/2017 | 2,012 | 280 | N/A | 361 | N/A |
3/31/2017 | 1,901 | 259 | N/A | 352 | N/A |
12/31/2016 | 1,790 | 237 | N/A | 342 | N/A |
9/30/2016 | 1,627 | 174 | N/A | 317 | N/A |
6/30/2016 | 1,464 | 111 | N/A | 292 | N/A |
3/31/2016 | 1,462 | 143 | N/A | 298 | N/A |
12/31/2015 | 1,461 | 174 | N/A | 305 | N/A |
9/30/2015 | 1,533 | 231 | N/A | 192 | N/A |
6/30/2015 | 1,605 | 287 | N/A | 79 | N/A |
3/31/2015 | 1,573 | 274 | N/A | 31 | N/A |
12/31/2014 | 1,540 | 262 | N/A | -18 | N/A |
9/30/2014 | 1,500 | 262 | N/A | -50 | N/A |
6/30/2014 | 1,460 | 263 | N/A | -82 | N/A |
3/31/2014 | 1,366 | 250 | N/A | -17 | N/A |
12/31/2013 | 1,272 | 238 | N/A | 48 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van 1345 boven de spaarquote ( 2.3% ) ligt.
Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van 1345 naar verwachting sneller zal groeien dan de markt Hong Kong
Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van 1345 naar verwachting de komende 3 jaar aanzienlijk zal groeien.
Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van 1345 naar verwachting sneller zal groeien dan de markt Hong Kong.
Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van 1345 naar verwachting sneller zal groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 1345 naar verwachting over 3 jaar hoog zal zijn